Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Pharmaceutical Products — Investment Income Interest

Similar metrics at other companies

Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Investment Income Interest
$3.41M+49.1%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Interest income, net
$114.8M-2.6%
Syndax Pharmaceuticals logo
SNDXBiopharmaceutical Cancer Therapeutics — Interest Income Expense Net
-$3.56M+50.4%
Ligand Pharmaceuticals logo
LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Income
$6.66M+276%
Baxter International logo
BAXPharmaceuticals — Segment operating income
$46M-27.0%
Nelnet logo
NNIInvestment interest — Investment interest
$40.2M-2.9%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's pharmaceutical products — investment income interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's pharmaceutical products — investment income interest?
Amphastar Pharmaceuticals (AMPH) reported pharmaceutical products — investment income interest of $2.4M in Q1 2026.
How has Amphastar Pharmaceuticals's pharmaceutical products — investment income interest changed year-over-year?
Amphastar Pharmaceuticals's pharmaceutical products — investment income interest increased by 14.9% year-over-year, from $2.09M to $2.4M.
What does pharmaceutical products — investment income interest mean?
This metric represents the interest and investment income generated specifically by the assets and cash balances allocated to the pharmaceutical products business segment. It reflects the segment's ability to earn returns on its liquid assets or short-term investments. Monitoring this helps investors understand the non-operating financial contribution of the segment's capital base.